Futura Medical PLC
LSE:FUM

Watchlist Manager
Futura Medical PLC Logo
Futura Medical PLC
LSE:FUM
Watchlist
Price: 32 GBX 0.16%
Market Cap: 97.2m GBX
Have any thoughts about
Futura Medical PLC?
Write Note

Futura Medical PLC
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Futura Medical PLC
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Futura Medical PLC
LSE:FUM
Additional Paid In Capital
ÂŁ70.9m
CAGR 3-Years
2%
CAGR 5-Years
7%
CAGR 10-Years
8%
GlaxoSmithKline PLC
LSE:GSK
Additional Paid In Capital
ÂŁ3.5B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
3%
AstraZeneca PLC
LSE:AZN
Additional Paid In Capital
$35.2B
CAGR 3-Years
64%
CAGR 5-Years
35%
CAGR 10-Years
24%
Verona Pharma PLC
NASDAQ:VRNA
Additional Paid In Capital
$621.6m
CAGR 3-Years
18%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Additional Paid In Capital
$282m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
Dechra Pharmaceuticals PLC
LSE:DPH
Additional Paid In Capital
ÂŁ596m
CAGR 3-Years
13%
CAGR 5-Years
11%
CAGR 10-Years
17%
No Stocks Found

Futura Medical PLC
Glance View

Market Cap
95.7m GBX
Industry
Pharmaceuticals

Futura Medical Plc is a pharmaceutical group that develops products for both the prescription and consumer healthcare markets. The company is headquartered in Guildford, Surrey and currently employs 13 full-time employees. The company went IPO on 2006-07-10. The firm is focused on developing a portfolio of products based on its transdermal DermaSys technology. Its patented transdermal DermaSys technology provides rapid and targeted local delivery of medical treatments via the skin. The firm is engaged in developing a portfolio of products for therapeutic areas, such as sexual health, including erectile dysfunction, and pain relief. The firm's products include MED3000 and TPR100. The firm's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The firm has conducted a Phase III study using MED3000 in ED. TPR100 is a topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism.

FUM Intrinsic Value
15.77 GBX
Overvaluation 51%
Intrinsic Value
Price

See Also

What is Futura Medical PLC's Additional Paid In Capital?
Additional Paid In Capital
70.9m GBP

Based on the financial report for Jun 30, 2024, Futura Medical PLC's Additional Paid In Capital amounts to 70.9m GBP.

What is Futura Medical PLC's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
8%

Over the last year, the Additional Paid In Capital growth was 0%. The average annual Additional Paid In Capital growth rates for Futura Medical PLC have been 2% over the past three years , 7% over the past five years , and 8% over the past ten years .

Back to Top